Novo Nordisk beats profit forecasts on bumper Wegovy pill sales - MSN
Novo Nordisk made more profit than Wall Street expected, driven by strong sales of Wegovy pills (the weight-loss drug semaglutide). The company's pill version of the drug is selling better than forecasters thought it would.
Strong Wegovy pill sales show people want a pill instead of a shot. That helps Novo keep up with Lilly in the weight-loss drug race.
- Novo Nordisk beat Wall Street profit forecasts
- Strong Wegovy pill sales drove the earnings beat
- Oral semaglutide is selling better than analysts expected
